Sarah E Davies1, Abigail Bishopp2, Simon Wharton2, Alice M Turner3, Adel H Mansur4. 1. Birmingham Regional Severe Asthma Service, Heart of England NHS Trust, Birmingham, UK; Institute of Inflammation and Ageing, University of Birmingham, UK. Electronic address: sarah.davies@heartofengland.nhs.uk. 2. Birmingham Heartlands Sleep Service, Heart of England NHS Trust, Birmingham, UK. 3. Birmingham Respiratory Department, Heart of England NHS Trust, Birmingham, UK; Institute of Applied Health Research, University of Birmingham, UK. 4. Birmingham Regional Severe Asthma Service, Heart of England NHS Trust, Birmingham, UK; Institute of Inflammation and Ageing, University of Birmingham, UK.
Abstract
INTRODUCTION: A high prevalence of OSA has been observed in asthma populations, with detrimental impact on clinical outcomes. AIM: To determine if CPAP treatment of co-existing OSA improves asthma-related symptoms and quality of life. METHODS: Literature review of EMBASE and MEDLINE databases prior to July 2017. Study populations included asthmatics with co-existing OSA treated with CPAP, and ≥1 asthma-related clinical outcome measure. RESULTS: 12 studies; 8 prospective quasi-experimental and 4 observational. Mean CPAP duration; 19.5 (2-100) weeks. Meta-analysis demonstrated significant improvement in mean Asthma Quality of Life Questionnaire scores (AQLQ and mini-AQLQ); 0.59 (95%CI; 0.25, 0.92), p = 0.0006. No significant improvement was demonstrated in forced expiratory volume in 1 s (FEV1)% predicted; 0.32 (95%CI; -2.84, 3.47), p = 0.84. Asthma Control Test/Asthma Control Questionnaire improved in 2 studies, with no improvement in 1 study. 4 studies demonstrated improvement in asthma daytime/night-time symptoms, and 3 studies showed improved asthma severity. CONCLUSION: Asthmatics with co-existing OSA can experience improved quality of life with CPAP treatment. This effect appears more pronounced in severe OSA or poorly controlled asthma.
INTRODUCTION: A high prevalence of OSA has been observed in asthma populations, with detrimental impact on clinical outcomes. AIM: To determine if CPAP treatment of co-existing OSA improves asthma-related symptoms and quality of life. METHODS: Literature review of EMBASE and MEDLINE databases prior to July 2017. Study populations included asthmatics with co-existing OSA treated with CPAP, and ≥1 asthma-related clinical outcome measure. RESULTS: 12 studies; 8 prospective quasi-experimental and 4 observational. Mean CPAP duration; 19.5 (2-100) weeks. Meta-analysis demonstrated significant improvement in mean Asthma Quality of Life Questionnaire scores (AQLQ and mini-AQLQ); 0.59 (95%CI; 0.25, 0.92), p = 0.0006. No significant improvement was demonstrated in forced expiratory volume in 1 s (FEV1)% predicted; 0.32 (95%CI; -2.84, 3.47), p = 0.84. Asthma Control Test/Asthma Control Questionnaire improved in 2 studies, with no improvement in 1 study. 4 studies demonstrated improvement in asthma daytime/night-time symptoms, and 3 studies showed improved asthma severity. CONCLUSION: Asthmatics with co-existing OSA can experience improved quality of life with CPAP treatment. This effect appears more pronounced in severe OSA or poorly controlled asthma.
Authors: Habib Mohammad Reazaul Karim; Antonio M Esquinas; Sally Ziatabar; Giuseppe Insalaco; Szymon Skoczyński; Irena Šarc; Luigi Ferini-Strambi; Leyla Pur Özyiğit; Thierry Hernández-Gilsoul; Subrata Kumar Singha; Laura Ciobanu; José Luis Sandoval Gutiérrez; Zbigniew Szkulmowski; Edoardo Piervincenzi; Margarida Aguiar; Mohamad F El-Khatib; Nadia Corcione; Aslıhan Gürün Kaya; Aydın Çiledağ; Akın Kaya; Gabriele Valli; Paola Pierucci; Onofrio Resta; Paschalis Steiropoulos; Francesca De Marco; Vania Caldeira; Bushra A Mina Journal: Turk Thorac J Date: 2020-07
Authors: Xiaoshu Cao; Cristina de Oliveira Francisco; T Douglas Bradley; Nasim Montazeri Ghahjaverestan; Susan M Tarlo; Matthew B Stanbrook; Kenneth R Chapman; Mark Inman; Azadeh Yadollahi Journal: Nat Sci Sleep Date: 2022-05-06
Authors: Fatema Al-Lawati; Saif M Al-Mubaihsi; B Jayakrishnan; Sayed Rizvi; Mohammed A Al-Abri Journal: Ann Thorac Med Date: 2022-04-19 Impact factor: 2.535
Authors: Li Liang; Xin Gu; Hai Ji Shen; Yu Heng Shi; Yao Li; Jie Zhang; Yan Yan Chen; Zhen He Chen; Jia Yun Ma; Qing Yun Li Journal: Front Physiol Date: 2021-08-27 Impact factor: 4.566